0
0
Singapore – A major international clinical trial has found that aspirin, despite its widespread use and potential benefits in other contexts, does not significantly reduce the risk of colorectal cancer recurrence after standard treatment.
The ASCOLT trial, led by the National Cancer Center Singapore, involved over 1,500 patients with high-risk colorectal cancer. Participants were randomly assigned to receive either aspirin or a placebo for three years following their initial treatment.
After five years of follow-up, researchers observed no statistically significant difference in disease-free survival or overall survival between the two groups. While the aspirin group showed slightly better outcomes, the confidence intervals were wide, suggesting that the true effect could range from a slight benefit to no effect at all.
“This trial provides the first robust, randomized evidence on the role of aspirin in preventing colorectal cancer recurrence,” said [Insert quote from a lead researcher]. “While we didn’t find the significant benefit we hoped for, the study provides valuable insights into the limitations of aspirin in this setting.”
Researchers are now exploring potential benefits of aspirin in specific subgroups of patients, such as those with certain genetic mutations.
This study has significant implications for the treatment of colorectal cancer, suggesting that alternative strategies may be needed to improve long-term outcomes for patients.
Disclaimer: This is a simplified news article. For the most accurate and comprehensive information, please refer to the original research published in The Lancet Gastroenterology & Hepatology.
